We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK, XenoPort Provide FDA Answer to Complete Response on Horizant
GSK, XenoPort Provide FDA Answer to Complete Response on Horizant
November 12, 2010
The FDA has accepted GlaxoSmithKline (GSK) and XenoPort’s answer to a complete response letter on the companies’ NDA for the restless legs syndrome (RLS) drug Horizant.